All In Biotech

Drug Trial Radar · NCT03792555

A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve)

A Double-blind, Placebo-controlled, Randomized Withdrawal Study to Evaluate the Safety, Pharmacokinetics and Efficacy of CRN00808 in Patients With Acromegaly That Are Responders to Octreotide LAR or Lanreotide Depot (ACROBAT Evolve)

Last checked: Nov 20, 2026Latest source record: Mar 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

13

Actual

Start

Mar 11, 2019

Primary completion

Jul 15, 2020

Study completion Aug 12, 2020

Sponsor

Lead sponsor
Crinetics Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Jan 3, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 2 double-blind, placebo-controlled, randomized withdrawal study is designed to evaluate the safety, efficacy, and pharmacokinetics of paltusotine (formerly CRN00808) in subjects with acromegaly that are responders to octreotide LAR or lanreotide depot.

Conditions

  • Acromegaly

Interventions

  • PaltusotineDrug

    Paltusotine, capsules, once daily by mouth

  • PlaceboDrug

    Placebo, capsules, once daily by mouth

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Responder Criteria Was Based on the Mean of Two Consecutive Insulin-like Growth Factor-1 [IGF-1] Measurements ≤ULN at Week 13Time frame: 13 Weeks

Locations

11 sites in 8 countries. Site status is shown where the registry gives one.

  • Ohio State University

    Columbus, Ohio

  • The Research Institute of Dallas

    Dallas, Texas

  • CETI - Centro de Estudos em Terapias Inovadoras

    Curitiba, Brazil

  • CPQuali Pesquisa Clinica

    São Paulo, Brazil

  • General Hospital of Athens "Gennimatas"

    Athens, Greece

  • Semmelweis University Faculty of Medicine

    Budapest, Hungary

  • University of Pécs Medical School

    Pécs, Hungary

  • Endocrine, Diabetes and Research Centre, Wellington Hospital

    Wellington, New Zealand

  • The Centre of Postgraduate Medical Education

    Warsaw, Poland

  • Clinical Centre Serbia, Clinic for Endocrinology, Diabetes and Metabolic Diseases

    Belgrade, Serbia

  • National Institute of Endocrinology and Diabetology

    Ľubochňa, Slovakia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.